The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
MGI received medical device certification clearance for its MGISEQ-200 and MGISEQ-2000 instruments.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.
The kits cover the primary genetic targets currently used for assessing the compatibility of hematopoietic cell donors with recipients.
Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round.
Through the deal, the companies aim to bring new next-generation sequencing-based oncology diagnostic kits to the Chinese market.
The new BGISEQ-50, a smaller version of the BGISEQ-500, will have research and clinical applications, and BGI plans to register it with the CFDA, too.
China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.